R
RTW Investments, LP
+ HoldingZLAB
-11.48%
3M Return
$22.500
-0.585 (-2.60%)At close
Loading chart…
- High
- 22.800
- Open
- 22.300
- VWAP
- 22.47
- Volume
- 849.72K
- Mkt Cap
- 1.73B
- Low
- 22.120
- Amount
- 19.10M
- EV/EBITDA, TTM
- -5.92
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
AI analysis of Zai Lab Ltd (ZLAB)
HoldZai Lab Ltd is currently priced at $24.99, which is below the average analyst price target of $40.50, indicating potential upside. However, the stock has a low RSI of 43.54, suggesting it is nearing oversold conditions, but the recent insider selling has increased by 126%, which raises concerns about the stock's short-term stability.
Analyst Ratings (3)
+113.02% upside
Buy
2 Buy
1 Hold
0 Sell
Current: 22.50
Low
25.70
Average
47.93
High
74.00
JPMorgan
Overweight
$36
2026-08-27
JPMorgan
2026-08-27
Price Target
$36
Overweight
Citi
Buy
$45
2026-08-07
Citi
2026-08-07
Price Target
$45
Buy
Citi
Buy
$44
2026-05-08
Citi
2026-05-08
Price Target
$44
Buy
JPMorgan
Overweight
$32
2026-03-18
JPMorgan
2026-03-18
Price Target
$32
Overweight
Cantor Fitzgerald
Overweight
$37
2026-02-27
Cantor Fitzgerald
2026-02-27
Price Target
$37
Overweight
Valuation Metrics
The current forward P/E ratio for Zai Lab Ltd (ZLAB) is 0.00, compared to its 5-year average forward P/E of -16.19.
Whales holding ZLAB
Events Timeline
News
9.010-14NewsfilterZai Lab to Present ZL-1503 Clinical Trial Data at ACAAI 2026
9.509-17CNBCChinese AI Companies Struggle with Revenue Growth
- 8.509-17Newsfilter
Chinese AI Models Generate Only 10% of Revenue Compared to U.S. Rivals
8.509-14CNBCZ.ai Plans to Raise $5 Billion Through Share Placement and Bonds
- 8.509-14Newsfilter
Z.ai Plans $5 Billion Fundraising, Shares Plunge Over 10%
ZLAB FAQ — answered by Alphio AI
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Zai Lab Ltd is currently priced at $24.99, which is below the average analyst price target of $40.50, indicating potential upside. However, the stock has a low RSI of 43.54, suggesting it is nearing oversold conditions, but the recent insider selling has increased by 126%, which raises concerns about the stock's short-term stability.
3 analysts cover ZLAB: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 47.93.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.